Cargando…

Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema

Background: Nanostructured lipid carriers (NLCs) are emerging as attractive drug carriers in transdermal drug delivery. The surface modification of NLCs with cell-penetrating peptides (CPPs) can enhance the skin permeation of drugs. Purpose: The objective of the current study was to evaluate the abi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Shanshan, Tian, Baocheng, Han, Jingtian, Zhang, Jing, Shi, Yanan, Lv, Qingzhi, Li, Keke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683961/
https://www.ncbi.nlm.nih.gov/pubmed/31447556
http://dx.doi.org/10.2147/IJN.S205295
_version_ 1783442193514496000
author Gao, Shanshan
Tian, Baocheng
Han, Jingtian
Zhang, Jing
Shi, Yanan
Lv, Qingzhi
Li, Keke
author_facet Gao, Shanshan
Tian, Baocheng
Han, Jingtian
Zhang, Jing
Shi, Yanan
Lv, Qingzhi
Li, Keke
author_sort Gao, Shanshan
collection PubMed
description Background: Nanostructured lipid carriers (NLCs) are emerging as attractive drug carriers in transdermal drug delivery. The surface modification of NLCs with cell-penetrating peptides (CPPs) can enhance the skin permeation of drugs. Purpose: The objective of the current study was to evaluate the ability of the cell-penetrating peptide (CPP) polyarginine to translocate NLCs loaded with lornoxicam (LN) into the skin layers and to evaluate its anti-inflammatory effect. Methods: The NLCs were prepared using an emulsion evaporation and low temperature solidification technique using glyceryl monostearates, triglycerides, DOGS-NTA-Ni lipids and surfactants, and then six histidine-tagged polyarginine containing 11 arginine (R11) peptides was modified on the surface of NLCs. Results: The developed NLCs formulated with LN and R11 (LN-NLC-R11) were incorporated into 2% HPMC gels. NLCs were prepared with a particle size of (121.81±3.61)–(145.72±4.78) nm, and the zeta potential decreased from (−30.30±2.07) to (−14.66±0.74) mV after the modification of R11 peptides. The encapsulation efficiency and drug loading were (74.61±1.13) % and (7.92±0.33) %, respectively, regardless of the surface modification. Cellular uptake assays using HaCaT cells suggested that the NLC modified with R11 (0.02%, w/w) significantly enhanced the cell internalization of nanoparticles relative to unmodified NLCs (P<0.05 or P<0.01). An in vitro skin permeation study showed better permeation-enhancing ability of R11 (0.02%, w/w) than that of other content (0.01% or 0.04%). In carrageenan-induced rat paw edema models, LN-NLC-R11 gels inhibited rat paw edema and the production of inflammatory cytokines compared with LN-NLC gels and LN gels (P<0.01). Conclusion: In our investigation, it was strongly demonstrated that the surface modification of NLC with R11 enhanced the translocation of LN across the skin, thereby alleviating inflammation.
format Online
Article
Text
id pubmed-6683961
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66839612019-08-23 Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema Gao, Shanshan Tian, Baocheng Han, Jingtian Zhang, Jing Shi, Yanan Lv, Qingzhi Li, Keke Int J Nanomedicine Original Research Background: Nanostructured lipid carriers (NLCs) are emerging as attractive drug carriers in transdermal drug delivery. The surface modification of NLCs with cell-penetrating peptides (CPPs) can enhance the skin permeation of drugs. Purpose: The objective of the current study was to evaluate the ability of the cell-penetrating peptide (CPP) polyarginine to translocate NLCs loaded with lornoxicam (LN) into the skin layers and to evaluate its anti-inflammatory effect. Methods: The NLCs were prepared using an emulsion evaporation and low temperature solidification technique using glyceryl monostearates, triglycerides, DOGS-NTA-Ni lipids and surfactants, and then six histidine-tagged polyarginine containing 11 arginine (R11) peptides was modified on the surface of NLCs. Results: The developed NLCs formulated with LN and R11 (LN-NLC-R11) were incorporated into 2% HPMC gels. NLCs were prepared with a particle size of (121.81±3.61)–(145.72±4.78) nm, and the zeta potential decreased from (−30.30±2.07) to (−14.66±0.74) mV after the modification of R11 peptides. The encapsulation efficiency and drug loading were (74.61±1.13) % and (7.92±0.33) %, respectively, regardless of the surface modification. Cellular uptake assays using HaCaT cells suggested that the NLC modified with R11 (0.02%, w/w) significantly enhanced the cell internalization of nanoparticles relative to unmodified NLCs (P<0.05 or P<0.01). An in vitro skin permeation study showed better permeation-enhancing ability of R11 (0.02%, w/w) than that of other content (0.01% or 0.04%). In carrageenan-induced rat paw edema models, LN-NLC-R11 gels inhibited rat paw edema and the production of inflammatory cytokines compared with LN-NLC gels and LN gels (P<0.01). Conclusion: In our investigation, it was strongly demonstrated that the surface modification of NLC with R11 enhanced the translocation of LN across the skin, thereby alleviating inflammation. Dove 2019-08-02 /pmc/articles/PMC6683961/ /pubmed/31447556 http://dx.doi.org/10.2147/IJN.S205295 Text en © 2019 Gao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gao, Shanshan
Tian, Baocheng
Han, Jingtian
Zhang, Jing
Shi, Yanan
Lv, Qingzhi
Li, Keke
Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema
title Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema
title_full Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema
title_fullStr Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema
title_full_unstemmed Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema
title_short Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema
title_sort enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683961/
https://www.ncbi.nlm.nih.gov/pubmed/31447556
http://dx.doi.org/10.2147/IJN.S205295
work_keys_str_mv AT gaoshanshan enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema
AT tianbaocheng enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema
AT hanjingtian enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema
AT zhangjing enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema
AT shiyanan enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema
AT lvqingzhi enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema
AT likeke enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema